IQ Webinar Series: In-Vitro Release of Long Acting Injectables
May 9, 2023 - May 9, 2023
Workshop
Location: Virtual
Venue: Webex Webinar
Join the IQ Dissolution Working Group for a 3-day, virtual public workshop on In-Vitro Release of Long-Acting Injectables on 2, 4, and 9 May from 10-1 PM ET.
Dissolution of long-acting injectables is a rapidly evolving area and new to most scientists in the field. Most literature and conference content focuses on formulation and biopharmaceutics (PK, etc.) This webinar series will focus on the development and use of dissolution / in-vitro release methods, including industry case studies and some of the latest academic research.
This is a public workshop. Membership in the IQ Consortium is not required to attend.
Speakers and Moderators
• Kate Harris, AstraZeneca
• Heather Mead, AstraZeneca
• Vasiliki Paraskevopoulou, AstraZeneca
• Johanna Milsmann, Boehringer Ingelheim
• Sharadvi Thati, Bristol Myers Squibb
• Dawen Kou, Genentech
• Krutika Harish Jain, Gilead
• David Curran, GSK
• Marieta Duvnjak Romic, Novartis
• Marta Venczel, Sanofi
• Talia Flanagan, UCB
• Adam McCartan, University of Bath
• Randy Mrsny, University of Bath
• Nikoletta Fotaki, University of Bath
• Diane Burgess, University of Connecticut
Session 1: 02 May
- Introduction: LAI dosage forms and implications for in-vitro release (dissolution)
- Dissolution in practice for LAIs: IQ Survey Results
- What are we trying to model? Part 1: Biology of subcutaneous tissue
Session 2: 04 May
- Business/portfolio perspective on LAIs
- Regulatory considerations for LAIs: case study
- Positive and negative experiences with instrumentation: USP4 and USP7
- IVR of in-situ-forming gels
Session 3: 09 May
- What are we trying to model? Part 2: Biology of muscle tissue
- Biorelevant media for LAIs
- Successful application of NanoDis instrument for a nanoparticle formulation
- Panel discussion